{
    "root": "03a7ffa9-1fe3-4844-8095-4d2945484441",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Metoprolol succinate",
    "value": "20250219",
    "ingredients": [
        {
            "name": "METOPROLOL SUCCINATE",
            "code": "TH25PD4CCB"
        },
        {
            "name": "ACETYLTRIBUTYL CITRATE",
            "code": "0ZBX0N59RZ"
        },
        {
            "name": "Silicon Dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "Hydroxypropyl Cellulose, Unspecified",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYDROGENATED COTTONSEED OIL",
            "code": "Z82Y2C65EA"
        },
        {
            "name": "METHYLENE CHLORIDE",
            "code": "588X2YUY0A"
        },
        {
            "name": "ETHYLCELLULOSE (10 MPA.S)",
            "code": "3DYK7UYZ62"
        }
    ],
    "indications": "Metoprolol succinate extended-release tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure. ( 1.3)",
    "contraindications": "Administer once daily. Titrate at weekly or longer intervals as needed and tolerated. ( 2 ) Hypertension: Starting dose is 25 to 100 mg. ( 2.1 ) Angina Pectoris: Starting dose is 100 mg. ( 2.2 ) Heart Failure: Starting dose is 12.5 or 25 mg. ( 2.3 ) Switching from immediate-release metoprolol to metoprolol succinate extended-release tablets: use the same total daily dose of metoprolol succinate extended-release tablets. ( 2)",
    "warningsAndPrecautions": "Metoprolol succinate extended-release tablets USP, 25 mg are white to off-white, oval shaped, film-coated tablets, debossed with “M” and “1” separated by breakline on one side and breakline on other side. They are supplied in the following blistercards and unit dose boxes:\n                  Blistercards of 30                                                                           NDC 0615-7823-39\n                  Blistercards of 28                                                                           NDC 0615-7823-28\n                  Blistercards of 15                                                                           NDC 0615-7823-05\n                  Unit dose boxes of 30                                                                    NDC 0615-7823-30\n                  Metoprolol succinate extended-release tablets USP, 50 mg are white to off-white, round shaped, film-coated tablets, debossed with  “M” and “2” separated by breakline on one side and plain on other side. They are supplied in the following blistercards:\n                  Blistercards of 30                                                                          NDC 0615-7824-39\n                  Blistercards of 28                                                                          NDC 0615-7824-28\n                  Blistercards of 15                                                                          NDC 0615-7824-05\n                  Store at 20°-25°C (68°-77°F); [See USP Controlled Room Temperature.]",
    "adverseReactions": "Metoprolol succinate extended-release tablets are contraindicated in severe bradycardia, second- or third-degree heart block, cardiogenic shock, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product."
}